Basem Mishriky is an Endocrinology/Metabolic physician affiliated with Duke University Health System. OpenAlex indexes 45 publications with 1,227 citations (h-index 15).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Industry payments
11 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Novo Nordisk IncProgram year20241 payment
- Abbott LaboratoriesProgram year20233 payments
- Novo Nordisk IncProgram year20232 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
46.9%Statin15.9%Atorvastatin Calcium65%Rosuvastatin Calcium22%Pravastatin Sodium9%Simvastatin4%Part D≥124 patientsCalcium channel blocker9.1%Amlodipine Besylate96%Amlodipine Besylate-Benazepril4%Part D<11 patients+ 7 more classes in this area
Metabolism & gastrointestinal
25.7%GLP-1 receptor agonist6.2%Ozempic61%Trulicity18%Mounjaro14%Rybelsus7%Part D<11 patientsBiguanide (metformin)5.6%Metformin Hcl56%Metformin Hcl Er44%Part D≥36 patients+ 7 more classes in this area
Nervous system
11.7%SSRI6.4%Sertraline Hcl31%Trazodone Hcl30%Fluoxetine Hcl18%Escitalopram Oxalate15%Citalopram Hbr7%Part D<11 patientsGabapentinoids3.3%Gabapentin84%Pregabalin16%Part D<11 patients+ 4 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- A meta‐analysis of randomized controlled trials evaluating sodium‐glucose co‐transporter 2 inhibitors and incidental atrial fibrillation—Is there a true benefit?
Diabetes/Metabolism Research and Reviews
2023 - Diabetes-Related Microvascular Complications – A Practical Approach
Primary Care Clinics in Office Practice
2022
Similar KOLs
Other experts from the same institution or the same specialty.
Cynthia Guy, MD
Duke University Health System
Richard Shannon, MD
Duke University Health System
Gerald Lazarus, MD
Duke University Health System
Suheil Muasher, MD
Duke University Health System
Yousef Saleh Khader
Jordan University of Science and Technology
Jens Juul Holst
University of Copenhagen
Victor Montori, MD
Mayo Clinic
Christos Mantzoros, MD
Harvard Medical School
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”